Juno Therapeutics Inc. (JUNO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO)

JUNO 86.96

0.0%

Mar 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (64)	11/1/2017 1:49:35 PM
From: tuck	of 84

ASH abstracts out, and the JCAR017 study called TRANSCEND has produced results Juno can move forward with. I see the preconditioning regime is continued, though specifics are not given. Some CRS and neurotox, but nothing disastrous. JUNO stock is being allowed to keep it recent gains. High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next